Pancreatic cancer is incredibly difficult to shake. Even after surgery or chemotherapy, the disease may never go away completely. By some estimates, malignant tumors in the pancreas can recur in up to 80 percent of patients. Those with certain gene mutations…
Complexity of pancreatic cancer reproduced in the laboratory The team used machine learning to categorize the newly grown organoids based on their morphologies in defined groups for further systematic analyses. "We identified different phenotypes within the two subtypes epithelial and…
A domestic research team has developed an antibody candidate that could alleviate "cancer cachexia," a condition in which cancer patients lose weight and muscle strength. Animal tests confirmed effects in restoring appetite and reducing muscle and fat loss. A joint…
Newswise — ROCHESTER, Minn. — In an academic-industrial collaboration, Mayo Clinic is assessing in a clinical trial a new radiotracer in pancreatic cancer imaging. "The research will focus on pancreatic cancer and evaluate whether this radiotracer does what it's supposed to do,…
Tango Therapeutics offers an 82% ORR and notable durability in MTAP-deleted/RAS-mutant pancreatic cancer. Read more on TNGX stock here. - Tango Therapeutics offers an 82% ORR and notable durability in MTAP-deleted/RAS-mutant pancreatic cancer, outperforming historical controls. - I view the ESMO-driven sell-off…
Pancreatitis can promote clotting through inflammation, endothelial injury, immobility, and local tissue damage. Attention often focuses on clots in abdominal vessels, but deep vein thrombosis and pulmonary embolism can also occur. Existing tools such as BISAP, APACHE II, and Ranson…
Novocure (Nasdaq: NVCR) announced today that it has entered into a clinical trial collaboration and supply agreement with Verastem Oncology to evaluate the use of Novocure’s Tumor Treating Fields (TTFields) therapy with chemotherapy and VS-7375, Verastem’s investigational oral, potent and…
Tango Therapeutics was trading down on Friday after updated results from a mid-stage study of its pancreatic cancer candidate combined with Revolution Medicines’ recently approved Rasonque showed a lower response rate than previously reported. Tango previously revealed data in June…
MADRID — The combination of an experimental drug from Boston-based Tango Therapeutics and Revolution Medicines’ Rasonque led to tumor responses in 82 percent of patients with a certain type of advanced pancreatic cancer, clinical trial results reported Friday showed. The responses were…
Materials provided by Okayama University. Note: Content may be edited for style and length. Scientists Discover Mysterious 150,000-Year-Old Bone From an Extinct Human Relative in Chinese Cave After 150 Years, Scientists May Have Solved the Mystery of Westminster Abbey’s Roman Coffin…
Pancreatic cancer: early detection, new treatments such as KRAS drugs and vaccines, and survival.
An article joins this feed when it matches these terms. Each one is also a search of its own.